WESTMINSTER, Colo., June 6, 2018 /PRNewswire/ — CardioNXT and AFTx, related privately-held medical device companies, jointly announced today that the Real-time electrogram Analysis for Drivers of Atrial fibRillation (RADAR) clinical trial has reached full enrollment with 65 treated patients. The RADAR trial focuses on treating patients with Persistent and Long Standing Persistent Atrial Fibrillation (AF).  The […]